Asia: Alliance for Pharmaceuticals Sun Pharma and Mitsubishi Tanabe Team Up

Editor: Dominik Stephan

Sun Pharma has recently announced the initiation of a phased transfer of manufacturing and marketing rights in Japan for the 14 long-listed/established prescription brands acquired from Novartis.

Related Vendors

(Source: Public Domain / CC0 )

Mumbai/India – These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma KK to Sun Pharma’s subsidiary in Japan beginning October 2016.

Sun Pharma has also signed a strategic distribution alliance with Mitsubishi Tanabe Pharma Corporation for these 14 prescription brands. Under this alliance, following the transfer of manufacturing and marketing rights to Sun Pharma’s subsidiary in Japan, Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14 brands as well as provide information on their proper use to healthcare professionals.

According to President & Representative Director, Sun Pharma Japan Ltd, Isao Muramatsu, “Through this alliance we have the opportunity to leverage Mitsubishi Tanabe Pharma Corporation’s specialized expertise to create a strong business foundation for us in Japan. Sun Pharma will focus on expanding its sales channels in Japan’s pharmaceutical market while continuing to ensure a stable supply of medicines and healthcare information.”

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent